Hepatotoxicity induced by terazosin [3];Hepatotoxicidad por terazosina

Medicina Clinica

Volumn 120, Issue 3, 2003, Pages 118-

  Fernández Salazar, Luis ^a   Palencia García, Ángel ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMLODIPINE; ATENOLOL; BICARBONATE; CALCITRIOL; DOXAZOSIN; PRAZOSIN; RAMIPRIL; TERAZOSIN;

ADULT; ASTHENIA; CASE REPORT; CHRONIC KIDNEY FAILURE; ECHOGRAPHY; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; LETTER; LIVER TOXICITY; MALE; RENOVASCULAR HYPERTENSION; SKIN MANIFESTATION; VERTIGO;

EID: 0037329107     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042637     Document Type: Letter

References (6)

1. Dauer AD, Abraham PA, Cohen A, Deger G, Fleming L, Gennari FJ, et al. Terazosin: An effective once-daily monotherapy for the treatment of hypertension. Am J Med 1986;80:29-34.
2. Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin: An analysis of the veterans affairs cooperative study. J Urol 2000;163 (4):1134-7.
3. Sondres RC. Pharmacokinetics of Terazosin. Am J Med 1986;80:20-4.
4. Jungers P, Ganeval D, Pertuiset N, Chauveau P. Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. Am J Med 1986;80:94-9.
5. Lowe FC. Safety assesment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994;44:46-51.
6. Hernández-Cano N, Herranz P, Lázaro TE, Mayor M, Casado M. Severe cutaneus reaction due to terazosin. Lancet 1998;352:202-3.